Cleaning Validation for Reusable Surgical Instruments: Soil, Residue, Worst-Case Devices, and Acceptance Criteria

Why Cleaning Validation Demands Its Own Protocol

Cleaning is the foundational step in every reprocessing workflow. If residual soil remains on a reusable surgical instrument after cleaning, downstream disinfection or sterilization may be compromised — organic material can shield microorganisms from chemical and thermal kill mechanisms. FDA, EU MDR, and international standards treat cleaning validation as a separate study that must stand on its own evidence, not as a footnote to disinfection or sterilization validation.

This guide provides the protocol-level detail manufacturers need: test soil selection, analyte endpoints, worst-case device selection, manual vs automated methods, sample size, acceptance criteria, and report structure. It complements the broader ISO 17664 reprocessing validation article by going deeper into cleaning-specific study design and analytical methods.

Regulatory and Standards Framework

The Cleaning Validation Workflow

Cleaning validation follows a structured sequence. Skipping or combining steps is the most common source of FDA additional information requests and notified body findings.

Step 1: Device Grouping and Worst-Case Selection

Devices are grouped by design features that affect cleanability, not by product code or marketing name. Within each group, the worst-case device — the one most challenging to clean — is selected for testing.

Grouping criteria:

• Clinical use and soil type: Devices contacting blood vs. mucous membranes vs. skin
• Material compatibility: Stainless steel, aluminum, polymer, coated surfaces
• Design complexity: Lumens, hinges, serrations, blind holes, matted surfaces, spring-loaded mechanisms
• Surface area: Total surface area determines extraction volume and analyte concentration calculations

Worst-case device identification:

Select the device within each family with the greatest number of hard-to-clean features. Common worst-case features include:

Step 2: End-of-Life Conditioning

Before cleaning validation begins, devices undergo simulated-use conditioning to represent their maximum claimed reprocessing life. Per AAMI ST98 and FDA expectations:

• A minimum of six simulated-use cycles are performed (soiling, drying, cleaning, disinfection/sterilization)
• Each cycle includes full soiling, worst-case drying time, and complete reprocessing per the IFU
• Functional testing after conditioning confirms the device remains operational
• The last cycle is the validation cycle — soiled but not yet cleaned, to test the cleaning protocol at end of life

Step 3: Test Soil Selection

The test soil must simulate clinically relevant contamination. ASTM F3208-20 provides a framework for selection based on the device's intended clinical use.

Soiling procedure:

• Apply soil to all device surfaces, focusing on hard-to-clean areas identified in Step 1
• Actuate movable parts during soiling to simulate clinical use
• Immersion or targeted application depending on clinical scenario
• Allow soil to dry for the maximum clinically relevant delay (often 30–120 minutes at room temperature) to simulate worst-case transport time

Step 4: Cleaning Under Worst-Case Conditions

The cleaning protocol tested must represent the least rigorous implementation of the IFU — shortest time, lowest temperature, weakest concentration, minimum mechanical action. This is a critical FDA expectation.

Manual cleaning worst-case parameters:

Automated cleaning worst-case parameters:

Step 5: Residue Extraction and Analyte Testing

After cleaning, devices undergo extraction to recover residual soil for quantitative analysis.

Extraction methods:

• Immersion/sonication: Device submerged in extraction solution (e.g., reverse osmosis water, 1% SDS) with ultrasonic agitation at controlled temperature (typically 40–50 °C for 30 minutes)
• Flush/elution for lumened devices: Measured volume of extraction solution flushed through lumen; effluent collected
• Swabbing for surfaces: Used for specific localized areas; less common for full-device validation

Analytes and assay methods:

Per AAMI ST98, critical and semi-critical devices require visual inspection plus at least two quantitative, clinically relevant analytes. Protein is routinely the first; the second is selected based on clinical use (e.g., hemoglobin for blood-contacting devices, TOC for mixed soil).

ISO 15883-5 alert and action levels for protein:

Step 6: Visual Inspection

All devices must be visually inspected after cleaning. Visual inspection is a required pass/fail criterion regardless of quantitative results.

• Method: Trained analyst under controlled lighting (minimum 1,000 lux), with magnification (5–10×) for complex features
• Borescope/endoscope inspection for lumened devices to detect internal residue
• Acceptance: No visible soil on any surface, joint, lumen, or crevice

Step 7: Detergent Residue Evaluation

After quantitative analyte testing, cleaned devices should be evaluated for detergent residuals. Per AAMI ST98 and FDA expectations, detergent must be reduced to safe, non-toxic levels. This is typically demonstrated through:

• ISO cytotoxicity testing (ISO 10993-5) on the cleaned device extract — confirms residual detergent is below cytotoxic threshold
• Specific detergent assays if the extraction method may interfere with downstream testing
• This step is separate from soil removal validation and must not be omitted

Step 8: Controls

Sample Size Justification

AAMI ST98 specifies sample size requirements that differ from earlier TIR30 guidance:

1. A minimum of three data points per endpoint test
2. All data points must be within stated acceptance criteria
3. The standard deviation of the data set is calculated and added to the highest data point; the result must not exceed the acceptance criterion
4. If the sum exceeds the criterion, the sample size must be increased

Manual vs Automated Cleaning Validation

The choice between manual and automated cleaning affects study design significantly.

Key point: If the IFU offers both manual and automated options, each must be validated separately.

Common Deficiencies and How to Avoid Them

Cleaning Validation Report Structure

A well-structured report facilitates FDA review and notified body audit. Recommended sections:

Decision Tree: Which Cleaning Validation Path Applies

Is the device reusable?
├── No → Cleaning validation not required
└── Yes
    ├── Is it supplied non-sterile requiring initial processing?
    │   └── Yes → Validate initial cleaning per IFU
    ├── Is it critical (contacts sterile tissue)?
    │   └── Yes → ST98: visual + ≥2 analytes + worst-case
    ├── Is it semi-critical (contacts mucous membranes)?
    │   └── Yes → ST98: visual + ≥2 analytes + worst-case
    └── Is it non-critical (contacts intact skin only)?
        └── Yes → ST98 allows reduced rigor (visual + 1 analyte may suffice)
            ├── Manual cleaning in IFU?
            │   └── Yes → Validate manual path separately
            └── Automated cleaning in IFU?
                └── Yes → Validate automated path per ISO 15883-5

Submission Evidence: What Goes Into Your 510(k) or Technical File

For FDA submissions, Emergo by UL (March 2026) notes that reprocessing is one of three areas where FDA expectations are "usually significantly different from most other regions of the world" — specifically, FDA expects device-based cleaning test data (summary or full report), whereas most other regulators require only sterilization validation.

Key Takeaways

• AAMI ST98:2022 is now the primary standard for cleaning validation, replacing TIR30 with updated acceptance criteria including TOC ≤ 12 µg/cm²
• Critical and semi-critical devices require visual inspection plus at least two quantitative analytes (protein + hemoglobin, TOC, or carbohydrate)
• Worst-case device selection is based on design complexity, not product code; document the rationale
• End-of-life conditioning (minimum 6 cycles) must precede the validation cleaning cycle
• Test soil must be clinically relevant per ASTM F3208-20
• Manual and automated cleaning paths require separate validation studies
• Sample size adequacy is determined by the SD + max calculation, not just minimum device count

Sources

• ANSI/AAMI ST98:2022 — Cleaning validation of health care products
• ISO 15883-5:2021 — Washer-disinfectors, Part 5: Performance requirements and test method criteria for demonstrating cleaning efficacy
• ASTM F3208-20 — Standard Guide for Selecting Test Soils for Validation of Cleaning Methods for Reusable Medical Devices
• ISO 17664-1:2021 — Processing of health care products, Part 1: Critical and semi-critical medical devices
• FDA Guidance — Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling (March 2015)
• Emergo by UL — US FDA Reprocessing Expectations (March 2026)
• Nelson Labs — How to Perform Cleaning Validations for Semi-Critical and Critical Devices According to ANSI/AAMI ST98
• AAMI ST98:2022 acceptance criteria: Protein ≤ 6.4 µg/cm², Hemoglobin ≤ 2.2 µg/cm², TOC ≤ 12 µg/cm², Carbohydrate ≤ 1.8 µg/cm²
• ISO 20417:2026 — Medical device labeling requirements
• TÜV SÜD — Reprocessing Validation for Reusable Medical Devices (whitepaper)
• LexaMed — Cleaning Validation for Reusable Medical Devices (March 2025)